Par Drugs & Chemicals Ltd Q3 FY26: ₹29.34 Cr Revenue, 728% PAT Jump, P/E 8.57 – Pharma to Real Estate Plot Twist?
1. At a Glance – The Antacid That Wants to Become a Real Estate Developer
₹119 crore market cap. ₹96.9 share price. P/E of 8.57 in a pharma industry trading at ~29.6. Debt: Zero. ROCE: 18.4%. Promoter holding: 73.4%. Q3 FY26 Revenue: ₹29.34 crore. Q3 PAT: ₹4.80 crore. QoQ revenue growth: 37.2%. QoQ PAT growth: 728%.
And just when you think this is a quiet, boring antacid API company… boom.
In February 2025, the board approved a ₹95 crore slump sale of its pharma business and decided to pivot into real estate, capital markets, and renewable energy.
Yes. From magnesium hydroxide to maybe housing society brochure printing.
So here we are — a profitable, debt-free, niche pharma player with strong Q3 numbers… that has officially decided to change its life path like a mid-life crisis uncle buying farmland.
Is this value unlocking? Or value evaporating?
Let’s open the chemistry lab.
2. Introduction – From Antacids to Assets
Founded in 1982, Par Drugs & Chemicals Ltd started as a manufacturer of APIs and fine chemicals. The company has a manufacturing facility in Bhavnagar, Gujarat with a capacity of 9,700 MT annually.
Its specialty? Antacid molecules. Magnesium salts, aluminium hydroxide gel, precipitated silica, colloidal silicon dioxide, sucralfate USP — basically the silent heroes of India’s acidity problem.
Exports contribute ~21% of revenue (FY23), domestic ~79%. Business mix: APIs ~57%, Fine Chemicals ~42% (9MFY23).
For decades, this was a typical small-cap chemical-pharma hybrid:
Moderate margins
Steady ROE around mid-teens
No debt
Conservative promoter ownership
Then in February 2025, the board approved a ₹95 crore slump sale of its pharma assets to a related party, Phal-Jig Fine Chemicals Pvt Ltd. EGM approved. Object clause altered.
Suddenly, we are talking:
Real estate
Capital markets
Renewable energy
Question: If you’re making money selling antacid APIs, why suddenly pivot to property and stock markets?
Is the pharma business undervalued? Or was something not so shiny under the microscope?
Let’s examine the business model first.
3. Business Model – WTF Do They Even Do?
Original business:
They manufacture Active Pharmaceutical Ingredients (APIs) and fine chemicals. Specifically:
Magnesium Salts
Magnesium Hydroxide
Magnesium Trisilicate
Magnesium Carbonate
Magnesium Oxide variants
Dried Aluminium Hydroxide Gel Used in antacid formulations and industrial applications.
Blended Products Magaldrate, Aluminium Magnesium Silicate, etc.
Precipitated Silica & Sodium Aluminium Silicate Used in pesticides, detergents, coatings.
Sucralfate USP Used for duodenal ulcers and GERD.
In simple language:
They make the raw material that goes into antacid tablets and formulations.
Customers include:
Essential Drugs Company Ltd
Pfizer Ltd
United Phosphorus Ltd
Cipla Ltd
So basically, they supply the “boring but essential” base ingredients to larger pharma brands.
This is a B2B, volume-driven, moderate-margin business. No branding glamour. No marketing circus. Just chemistry and compliance.
And honestly? That’s usually good. Boring businesses often make steady money.
But here’s the twist:
The pharma unit has been approved for slump sale for ₹95 crore.
Which means the core revenue engine is being sold.
So the future company might not even be pharma.
Tell me — if you bought shares thinking “API company”, and tomorrow it becomes “real estate & capital markets”, are you comfortable?
4. Financials Overview – The Q3 FY26 Popcorn Moment
